Cole et al. show that ClpP, a mitochondrial protease, is overexpressed in a large fraction of human acute myeloid leukemias (AMLs) and that inactivation of ClpP selectively kills these AML cells via inhibition of oxidative phosphorylation and mitochondrial metabolism.
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In Brief Cole et al. show that ClpP, a mitochondrial protease, is overexpressed in a large fraction of human acute myeloid leukemias (AMLs) and that inactivation of ClpP selectively kills these AML cells via inhibition of oxidative phosphorylation and mitochondrial metabolism.
INTRODUCTION
The cytoplasmic/nuclear proteasome complex is a well recognized therapeutic target, and proteasome inhibitors have been approved for the treatment of hematologic malignancies (Fisher et al., 2006; O'Connor et al., 2009; Richardson et al., 2005; Vij et al., 2012) . Mitochondria also possess a serine protease complex, ClpP, that is structurally similar to the cytoplasmic/ nuclear proteasome (Goard and Schimmer, 2014) , but little is known about the expression of this complex or the effects of its inhibition in malignant cells.
ClpP is encoded by a nuclear gene, translated in the cytoplasm, and imported into the mitochondrial matrix. There it is assembled into a tetradecamer consisting of seven repeated symmetric rings arranged in a stable double-ringed structure (Corydon et al., 1998; de Sagarra et al., 1999) , each end of which
Significance
Perturbations in the cytoplasmic and nuclear proteasome are known to contribute to the acquisition of malignant properties, but the importance of ClpP, a mitochondrial protease with structural homology to the proteasome, has not been established. We have now shown that loss of ClpP does not impact normal hematopoiesis, whereas ClpP inhibition kills human leukemic cells, including those with stem and progenitor activity, which may be attributable to their higher mitochondrial stress and a greater reliance on oxidative phosphorylation. These results suggest that targeting mitochondrial ClpP may be an attractive therapeutic strategy for a subset of human acute leukemias.
is capped by an AAA+ ATPase chaperone, ClpX (Kang et al., 2005) . Based on studies of its homologs in bacteria and its structural similarities to the cytoplasmic proteasome, the ClpP complex is thought to degrade damaged or misfolded proteins inside mitochondria.
Inhibition of ClpP in normal mice (Gispert et al., 2013) , humans (Jenkinson et al., 2013) , and C. elegans (Haynes et al., 2007 (Haynes et al., , 2010 has not been found to elicit much loss of viability. For example, Clpp À/À mice are viable but display infertility, slight growth retardation, and acquired hearing loss (Gispert et al., 2013) . Homozygous CLPP mutations have also been described in individuals from three human families (Jenkinson et al., 2013) . Similar to the mouse phenotype, these individuals have congenital hearing loss and premature ovarian failure.
In contrast, deregulating ClpP activity in certain bacteria, either through inhibition (Zeiler et al., 2012) or increased activation (Conlon et al., 2013) , is cytotoxic even when they are dormant or have acquired antibiotic resistance (Conlon et al., 2013) . Recently, we (Skrti c et al., 2011) and others (Lagadinou et al., 2013) demonstrated that leukemic cells, including those with stem and progenitor activity from patients with acute myeloid leukemia (AML) have an increased mitochondrial mass and reliance on oxidative phosphorylation. We therefore initiated a study to identify members of the mitochondrial proteome whose inhibition might reduce the viability of AML cells.
RESULTS

A Genetic Screen Identifies ClpP as Essential for the Viability of Leukemia Cells
We first sought to determine whether short hairpin RNA (shRNA)-mediated knockdown of any of the 1,300 members of the mitochondrial proteome would identify candidates that could reduce the viability of human leukemic cells using K562 cells as targets. Accordingly, we transduced K562 cells with a library of 54,021 shRNAs in barcoded lentiviral vectors targeting 11,255 nuclearly encoded genes. Twenty-one days after transduction, cells were harvested, genomic DNA was isolated, and the relative abundance of shRNA sequences present in the surviving cells was determined by array analysis of the barcodes. shRNAs able to reduce the viability or growth of K562 cells were inferred to be those not represented in the final cell population ( Figure S1A ). shRNAs targeting BCR and ABL1 were top hits (Figures S1A-S1C), therefore validating the robustness of the screen because K562 cells are dependent on the BCR-ABL1 fusion oncoprotein for survival (Dan et al., 1998) . In this screen, 2,422 shRNAs targeted 496 members of the mitochondrial proteome, and of the top 25 targets, four were mitochondrial proteases (NLN, ClpP, PARL, and PITRM1), with two targeting ClpP ranking in the top 1% of all hits in the screen ( Figures 1A-1C) . In contrast, the mitochondrial matrix protease Lon did not appear as a hit in our shRNA screen, and repetition of this experiment using shRNAs that produced high levels of target knockdown (both protein and mRNA) confirmed that Lon was not required for the growth and viability of TEX, OCI-AML2, or K562 leukemia cells ( Figure S1D and data not shown). Therefore, some, but not all, mitochondrial proteases are necessary for the viability of AML cells. Figure S1N ). In addition, we demonstrated that CLPP mRNA was increased in a subset of AML cells compared with normal hematopoietic cells and expressed similarly in the bulk and progenitor (CD34 + CD38
À ) populations of primary AML samples ( Figure S1O ). Gene expression analysis of previously characterized AML patient samples demonstrated that CLPP mRNA was similarly expressed in fractions enriched or depleted of leukemic stem cells (LSCs) defined by functional assays (p = 0.45) ( Figure S1P ). Analysis of TCGA data indicated that CLPP expression did not correlate with known AML mutations (Table S1 ). In primary AML patient samples, higher CLPP expression was associated with an increased expression of genes related to the mitochondrial unfolded protein response (mtUPR). This positive correlation was observed in both the LSC + and LSC À fractions of primary AML cells (Figures S1Q and S1R) . Therefore, increased ClpP may be a marker of increased mitochondrial stress in a subset of AML patients that is downstream of multiple genetic pathways. Analysis of the Cancer Cell Line Encyclopedia indicated that CLPP was highly expressed in AML cells but also increased in subsets of other hematologic malignancies, including multiple myeloma, various lymphomas, and chronic myeloid leukemia (CML). In addition, CLPP was highly expressed in solid tumors such as prostate cancer and sarcomas ( Figure S1S ). Therefore, ClpP may also be a relevant target for malignancies beyond AML.
Genetic Knockdown of ClpP Reduces the Growth and Viability of AML Cells with High ClpP Expression
We next tested the effects of ClpP knockdown on the growth and viability of AML cells. K562, TEX, OCI-AML2, and HL60 cells were transduced with lentiviral vectors expressing a control sequence or three independent shRNA sequences targeting CLPP. The shRNA sequences targeting CLPP showed robust target knockdown by both quantitative RT-PCR and immunoblotting ( Figures 2A-2D and data not shown). Knockdown of ClpP reduced the growth and viability of the K562, TEX, and OCI-AML2 cells that have high ClpP expression (Figures 2A-2C ) but not HL60 cells that express low basal levels of ClpP ( Figure 2D ). In addition, knockdown of ClpP in TEX cells reduced engraftment into the marrow of non-obese diabetic M0  M1  M2  M3  M4  M4E0S  M5  M5A  M5B  M6  M7  RAEB  RAEBT  T- Error bars represent SD. The box represents the first and third quartiles, whiskers represent the range, the center line represents the median, and the circles represent outliers. See also Figure S1 and Table S1 .
(NOD)/severe combined immunodeficiency-growth factor (SCID-GF) mice ( Figure 2E ).
Clpp Knockout Mice Are Viable with Normal Hematopoiesis To assess the effects of ClpP inhibition on normal hematopoiesis in vivo, we created constitutive ClpP-deficient mice. In wild-type (WT) mice, ClpP protein was expressed at low levels in the bone marrow, lung, kidney, and stomach but was more abundant in the pancreas, colon, testis, brain, and liver ( Figure S2A ). ClpP was absent in all tested tissues from Clpp À/À mice ( Figure S2B ). Clpp À/À mice are viable, although slightly smaller than their WT counterparts (Figures S2C and S2D) . Therefore, our mice are similar to those obtained by Gispert et al. (2013) , who reported that 80% of their Clpp À/À mice survived over 400 days but were infertile and had impaired hearing. The study by Gispert et al. (2013) did not report the effects of Clpp deficiency on hematopoiesis. We therefore studied hematopoiesis in our Clpp À/À mice.
Clpp À/À mice had normal numbers of all mature blood cell types in the circulation ( Figure 3A ) and normal numbers of phenotypically defined (Lin
+ ) progenitor cells in the bone marrow (Figure 3B) . In vitro colony assays confirmed the presence of equal numbers of progenitors in the bone marrow of WT and Clpp À/À mice ( Figure 3C Figure S2H ). This lack of any detectable effect of Clpp absence in murine hematopoiesis supports the potential feasibility of using ClpP inhibitors for the treatment of AML.
ClpP Interacts with Respiratory Chain Proteins and Mitochondrial Metabolism Enzymes
The function and substrates of mammalian ClpP are largely unknown. To gain insight into ClpP function, we used the BioIDmass spectrometry (BioID-MS) method to identify ClpP-interacting partners (Roux et al., 2012) . To identify interacting proteins using BioID-MS, a protein of interest is fused in-frame with a mutant E. coli biotin conjugating enzyme, BirA R118G (or BirA*). BirA* efficiently activates biotin but exhibits a reduced affinity for the activated molecule. Biotinoyl-AMP, therefore, simply diffuses away from BirA* and reacts with nearby amine groups, including those present on lysine residues in neighboring polypeptides. Following stringent cell lysis, biotinylated proteins can be affinity-purified and identified using mass spectrometry.
From this protein interaction screen, we identified 191 mitochondrial ClpP-interacting proteins, 49 of which preferentially interacted with WT or mutant ClpP over the unrelated mitochondrial matrix enzyme ornithine transcarbamoylase (OTC) (>3-fold spectral counts for BirA*-ClpP versus BirA*-OTC; Figure 4A ; Table S2). The proteins interacting with WT and mutant ClpP were similar. ClpX, the known regulatory subunit of ClpP, was the top hit in our interactome map. Most of the 48 other preferential ClpP-interacting proteins were components of the respiratory chain or enzymes involved in mitochondrial metabolism. Therefore, these data suggested that ClpP function could be important to maintain the integrity of mitochondrial metabolism.
Inhibition of ClpP Impairs Oxidative Phosphorylation
Given the interactions of ClpP with respiratory chain proteins and metabolic enzymes, we evaluated the effects of ClpP inhibition on oxidative phosphorylation. We found that knockdown of ClpP reduced basal oxygen consumption in OCI-AML2 cells ( Figure 4B ).
Succinate dehydrogenase subunit A (SDHA), a subunit of respiratory chain complex II, was a top hit in our interaction mapping experiment. Therefore, we also measured the effects of ClpP inhibition on the activity of respiratory chain complex II. Knockdown of ClpP reduced the enzymatic activity of complex II in OCI-AML2 cells ( Figure 4C ). Consistent with impaired complex II activity, knockdown of ClpP also increased mitochondrial reactive oxygen species (ROS) production (Figure 4D) . Using non-denaturing gels and immunoblotting, we also observed faster migrating bands of SDHA after ClpP knockdown, potentially representing the accumulation of non-functional misfolded or degraded SDHA ( Figure 4E ).
To determine whether the changes in oxidative phosphorylation were functionally important for cell death after ClpP inhibition, we examined the impact of ClpP inhibition in Rho (0) cells that lack mitochondrial DNA and oxidative phosphorylation. We knocked down ClpP in WT and Rho (0) 143B cells that expressed similar levels of ClpP protein ( Figures 4F-4H ). ClpP knockdown reduced the growth and viability of WT 143B cells but had less effect on the growth and viability of Rho (0) cells (Figure 4I) . In addition, we evaluated the impact of knocking down SDHA in OCI-AML2 cells. Knockdown of SDHA impaired complex II activity and reduced the growth and viability in these cells ( Figures S3A-S3C ). Therefore, these results support SDHA as a functionally important substrate for ClpP and a role for ClpP in maintaining oxidative phosphorylation in a subset of AML cells.
Loss of cell viability was not associated with changes in the mtUPR markers Hsp70 or CPN60 or changes in mitochondrial mass or structure in AML cell lines ( Figures S3D-S3H ).
A Small-Molecule ClpP Inhibitor Is Cytotoxic to AML Cells Recently, b-lactone inhibitors of bacterial ClpP were developed and shown to be toxic to several bacterial species (Zeiler et al., 2012) . As a chemical approach to evaluate the effects of ClpP inhibition on AML and normal cells, we synthesized the reported bacterial ClpP inhibitor (3RS,4RS)-3-(non-8-en-1-yl)-4-(2-(pyridin-3-yl)ethyl)oxetan-2-one (A2-32-01) ( Figure S4A ). A2-32-01 inhibited the enzymatic activity of recombinant bacterial ClpP similarly as the activity of the b-lactone inhibitors in the initial study (Zeiler et al., 2012;  Figure S4B ) as well as the enzymatic activity of recombinant human mitochondrial ClpP ( Figure 5A ). In addition, A2-32-01 inhibited cleavage of ClpP fluorogenic peptide substrates when added to lysates of mitochondria isolated from AML cells or intact AML cells ( Figure 5B ). A2-32-01 did not inhibit cytoplasmic chymotrypsin, trypsin, or caspase-like protease enzymatic activity when added to lysates of red blood cells that contained proteasome complexes but lacked mitochondria, therefore demonstrating its specificity for mitochondrial proteases ( Figure S4C ).
A2-32-01 induced cell death in TEX, OCI-AML2, and K562 leukemia cells at concentrations that matched its ability to inhibit ClpP activity, but was not toxic to HL60 leukemia cells, which express much lower levels of ClpP ( Figures 5C and 5D ). However, HL60 cells were more sensitive to the proteasome inhibitor bortezomib ( Figure S4D ). Similar to ClpP shRNA, A2-32-01 reduced the growth and viability of WT 143B cells but had little effect on the growth and viability of their Rho (0) counterparts ( Figure 5E ). Moreover, addition of A2-32-01 to OCI-AML2 cells produced no additional loss of growth and viability after knockdown of ClpP (Figure S4E) . We also evaluated analogs of A2-32-01. The related compound A2-58-06 had activity similar to A2-32-01, whereas A2-54-01 did not inhibit ClpP and did not reduce the growth and viability of TEX and OCI-AML2 cells ( Figures S4F and S4G) .
Although A2-32-01 was stable in DMSO, it was rapidly hydrolyzed when dissolved in cell culture medium, with >90% of the compound degraded within 1 hr ( Figure S4H ). We confirmed that degradation products were inactive (data not shown). This rapid degradation likely explains the high half-maximal inhibitory concentration (IC 50 ) of the compound.
Next we assessed the impact of A2-32-01 on primary AML and normal hematopoietic cells. A2-32-01 showed significant dosedependent killing of primary AML patient cells that expressed elevated levels of ClpP. In contrast, the same treatment had little effect on either normal hematopoietic cells or primary AML cells that expressed lower levels of ClpP ( Figures 6A-6C ). In fact, primary AML cells showed a strong positive correlation between ClpP expression and sensitivity to A2-32-01 ( Figure 6D ). Therefore, ClpP expression might serve as a biomarker for patients who would respond to ClpP inhibitors.
A2-32-01 Shows Anti-AML Activity in Xenograft Models of Human Leukemia Finally, we evaluated the anti-leukemia efficacy and toxicity of A2-32-01 in mouse models of leukemia. Dissolving A2-32-01 in corn oil preserved its stability while in solution, and the pharmacokinetics of A2-32-01 were determined after intraperitoneal (i.p.) injection of the compound into SCID mice (Figures S5A and S5B) . Next, we evaluated the efficacy and toxicity of A2-32-01 in mice xenografted with OCI-AML2 cells. Daily treatment with A2-32-01 delayed the growth of OCI-AML2 cells in SCID mice without evidence of liver, muscle, or renal toxicity (Figure 7A ; Figures S5C and S5D) . Moreover, tumors excised from mice treated for 5 days with A2-32-01 had reduced respiratory chain complex II activity compared with vehicle-treated controls ( Figure 7B ) and reduced enzymatic activity of ClpP ( Figure 7C ). Therefore, A2-32-01 inhibits growth and mitochondrial function of this AML cell line in vivo.
We also assessed the efficacy and toxicity of A2-32-01 in NOD-SCID mice engrafted intra-femorally with primary AML cells. A2-32-01 treated mice had significantly lower levels of leukemic engraftment compared to control-treated mice without evidence of toxicity ( Figure 7D) . Thus, inhibiting ClpP may be an effective strategy for a subset of AML patients.
DISCUSSION
The therapy for AML has remained largely unchanged over the last 20 years, and the outcome for most patients is poor. In search of more effective approaches, we found recently that blocking mitochondrial protein translation was selectively cytotoxic to AML cells (Skrti c et al., 2011) . This followed the discovery that a subset of AML cells have unique mitochondrial characteristics with increased mitochondrial biogenesis and increased reliance on oxidative phosphorylation that could be inhibited by targeting mitochondrial protein translation (Lagadinou et al., 2013; Skrti c et al., 2011) . Here we identify ClpP as a potential component of the mitochondrial proteome whose inhibition might be cytotoxic to AML cells. We found that ClpP is overexpressed in leukemic cells from a group of AML patients and that inhibition of ClpP selectively induces death in these cells without apparent toxicity to normal hematopoiesis. The fact that increased expression of ClpP occurs across all currently defined subtypes of AML based on their morphologic, cytogenetic, or mutational features, including those with a poor prognosis, lends further support to the possibility that ClpP may be an important therapeutic target for the treatment of AML. In addition, ClpP expression may be a useful biomarker to identify patients most likely to respond to ClpP inhibitors.
Little is known about the endogenous proteins that interact with ClpP in the mitochondria of mammalian cells. Here we identified that most of the proteins interacted with ClpP were components of the respiratory chain and mitochondrial metabolic enzymes. It is noteworthy that a similar set of ClpP substrates, including the respiratory chain complex component SDHA, were identified by Haynes et al. (2010) in their studies of ClpP function in C. elegans. Therefore, ClpP appears to function to maintain the integrity of the respiratory chain and mitochondrial metabolism.
In C. elegans, peptides generated by ClpP-mediated protein degradation are exported from the mitochondria via the transporter haf-1 and signal the mtUPR response in the nucleus (Haynes et al., 2007 (Haynes et al., , 2010 . Upon mitochondrial stress, levels of ClpP and mtUPR-associated genes increase. To date, the mechanisms by which ClpP regulates the mtUPR in mammalian cells remain unknown, and the mammalian homolog of haf-1 has not yet been defined.
In our study, gene expression analysis demonstrated that higher levels of ClpP were associated with greater expression of genes associated with the mtUPR. Because of increased mitochondrial mass, high metabolic and biosynthetic requirements, and imbalances between levels of nuclear and mitochondrial encoded proteins, we hypothesize that the mitochondria in a subset of AML and other cancer cells are under increased basal stress and have upregulated ClpP in response to these stressors. In support of this hypothesis, induction of mitochondrial protein aggregates through the overexpression of mutant OTC in COS-7 cells induced mtUPR and increased ClpP expression (Zhao et al., 2002) . Mechanisms that regulate ClpP expression in AML cells are unknown and are an important direction for future study. In COS-7 cells, the expression of ClpP may be regulated at the level of its promoter by a combination of CHOP, MURE1, and MURE2 sequences (Aldridge et al., 2007) . However, it is unknown whether these sequences also regulate ClpP expression in AML cells, and the transcription factors that bind these sites are unknown. In addition, regulation of ClpP may also occur at the level of protein translation and degradation.
We used the bacterial ClpP inhibitor A2-32-01 to examine the impact of inhibiting mitochondrial ClpP in AML because the compound cross-reacted with the mitochondrial isoform. However, it is important to note that the selectivity of A2-32-01 for mitochondrial ClpP over other mammalian targets, including other mitochondrial proteases, remains to be determined. In addition, A2-32-301 has poor stability in aqueous media, so this molecule would not have therapeutic applications, and its ability to reduce large bulk disease may be limited. Developing See also Figure S3 and Table S2 . See also Figure S4 .
potent, stable, and specific ClpP inhibitors based on alternate scaffolds is a priority to fully assess the efficacy and toxicity of ClpP inhibition in vivo. In AML cells, loss of viability after inhibition of ClpP was associated with impairment of mitochondrial metabolism and oxidative phosphorylation. This finding is consistent with prior studies demonstrating that AML cells and stem cells have an increased reliance on oxidative phosphorylation (Skrti c et al., 2011; Lagadinou et al., 2013) . The fact that elevated ClpP expression was not associated with any known molecular or clinical feature of AML is consistent with this variable phenotype and suggests that increased ClpP expression may be a consequence of multiple dysregulated pathways that converge to impact mitochondrial function and metabolism.
In addition to ClpP, our shRNA screen of the mitochondrial proteome identified three other mitochondrial proteases whose knockdown reduced the growth and viability of K562 cells (NLN, PARL, and PITRM1). Little is known about mitochondrial proteases as cancer targets and the impact of inhibiting select mitochondrial proteases in malignant cells. Potentially, these proteases could also be important therapeutic targets for AML given their role in regulating mitochondrial function. For example, PARL regulates PINK1 turnover, and knockdown of PARL promotes accumulation of PINK1 on the mitochondrial surface, leading to increased mitophagy (Greene et al., 2012) . However, further studies will be necessary to fully understand the efficacy and toxicity of inhibiting PARL and other mitochondrial proteases in vitro and in vivo.
Therefore, in summary, although AML may have significant molecular and genetic heterogeneity, the dysregulation of some biological pathways such as mitochondrial function and metabolism remain common and may be amenable to therapeutic exploitation.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for additional experimental procedures.
shRNA Screen to Identify Targets in the Mitochondrial Proteome To identify shRNA that reduced the growth and viability of AML cells, we performed a pooled lentiviral shRNA screen in K562 cells similar to one described previously (Ketela et al., 2011) . K562 cells were selected because of their robust transduction efficiencies, and their reliance on BCR-ABL1 signaling served as a positive control for the screen. K562 leukemia cells were transduced with a pooled lentiviral library consisting of 54,021 shRNAs in barcoded lentiviral vectors with puromycin selection markers targeting 11,255 nuclearly encoded genes. Of these, 34,600 were associated with known genes and transcripts. These sequences were considered in the analysis. Cells were transduced at a multiplicity of infection of 0.3, ensuring that each cell receives at most one shRNA. The day after infection, cells were treated with puromycin to select infected cells. Resistant clones, containing a lentiviral vector and its associated shRNA, were then grown in puromycin-containing medium for 21 days. After 21 days, cells were harvested, genomic DNA was isolated, and the abundance of barcoded sequences was identified by microarray analysis. In conducting our lentiviral shRNA, we performed two independent experiments utilizing the same amount of virus for transduction (inter-experiment or biological replicates). Each trial was ) 3 100%. shRNAs in the screen were ranked based on Log 2 (fold change) and percent depletion values. shRNAs were also grouped by target gene to assess whether multiple shRNAs targeting the same gene had high percent depletion scores. Genes encoding the mitochondrial proteome were identified using MitoCarta (http://www.broadinstitute.org/pubs/MitoCarta/).
Reverse-Phase Protein Array
A reverse phase protein array (RPPA) was generated by using samples from patients with AML, myelodysplastic syndrome (MDS), and normal CD34 + cells as described previously Kornblau et al., 2010 Pierce et al., 2013; Tibes et al., 2006) . The ClpP antibody was validated for use in the RPPA assay as described previously Kornblau et al., 2010 Pierce et al., 2013; Tibes et al., 2006) . Briefly, the rabbit monoclonal ClpP antibody (clone ab124822, Abcam) was validated to recognize only a single band corresponding to the expected molecular weight by immunoblotting. In addition, the sensitivity of the antibody in the RPPA assay was validated using an array of cell line lysates seeded in serials dilutions. The RPPA signal was linear over the range of dilutions. In addition, the signal obtained with cell lysate dilutions by RPPA correlated with the signal intensity by observed by immunoblotting (R 2 = 0.75). When the RPPA was optimized for detection of ClpP expression, patient and normal samples were printed in five serial dilutions onto slides along with normalization and expression controls. Slides were probed with anti-ClpP primary antibody (Abcam, catalog no. 124822) at 1:1,000 and a secondary antibody followed by colorimetric assay. Stained slides were analyzed using Microvigene software (Vigene Tech).
Primary AML and Normal Hematopoietic Cells
Primary mononuclear cells were isolated from peripheral blood samples from consenting patients with AML whose blast count was 80% or higher by low-density cells isolated by Ficoll density centrifugation. Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells were obtained from healthy consenting volunteers donating peripheral blood stem cells for allogeneic stem cell transplantation. All primary cells were cultured at 37 C in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% fetal bovine serum (FBS) and penicillin-streptomycin. Informed consent was obtained from all subjects for the collection and use of samples. The collection and use of human tissue for this study were approved by the University Health Network Institutional Review Board and Review Ethics Board of the University of British Columbia.
shRNA Knockdown of ClpP Construction of hairpin-pLKO.1 vectors (carrying a puromycin antibiotic resistance gene) containing shRNA sequences and production of shRNA viruses was performed as described previously (Simpson et al., 2012) . The shRNAs targeting the ClpP (accession no. NM_003321) coding sequence are as follows: ClpP shRNA1, 5 0 -GCCCATCCACATGTACATCAA-3 0 ; ClpP shRNA2, 5 0 -CACGATGCAGTACATCCTCAAÀ3 0 ; and ClpP shRNA3, 5 0 -
Lentiviral transduction was performed essentially as described previously (Xu et al., 2010) . Briefly, cells (5 3 10 6 ) were centrifuged and resuspended in 5 ml of medium containing protamine sulfate (5 mg/ml). 0.5 ml of virus (for adherent cells) and 2 ml of virus (for suspension cells) were added to the cells, followed by overnight incubation (37 C, 5% CO 2 ). Cells were centrifuged and washed, and fresh medium with puromycin (1mg/ml) was added the following day. Three days later, cells were cultured to measure viability and growth. Equal numbers of TEX cells transduced with shRNA targeting ClpP or control sequences (2 3 10 5 ) were injected into the right femur of sublethally irradiated NOD/SCID-GF mice with human transgenes producing interleukin-3 (IL-3), granulocyte/macrophage-stimulating factor (GM-CSF), and Steel factor (SF) (n = 10/group) (Nicolini et al., 2004) . 6 weeks after injection, mice were sacrificed, and the percentage of human CD45 + cells in the noninjected left femur was determined by flow cytometry. To examine T cell function in Clpp À/À and Clpp +/+ mice, 5 3 10 6 splenocytes/well were seeded in wells coated with 3 mg/ml hamster anti-mouse CD3 (clone 2C11-145, BD Biosciences) and 1 mg/ml hamster anti-mouse CD28 (clone 37.51, eBioscience) for 24 hr. For B cell activation, splenocytes (5 3 10 6 /well) were cultured for 24 hr with 10 mg/ml goat anti-mouse immunoglobulin M (IgM) (F(ab')2 fragment, Jackson ImmunoResearch). To assess activation status, cells were stained with fluorescence-conjugated antibodies against surface markers. Flow cytometry data were acquired using a FACSCanto II (BD Biosciences) flow cytometer and analyzed with the FlowJo analysis program.
Evaluation of Hematopoietic Progenitors in WT and
BioID-MS to Identify ClpP-Interacting Proteins
Stable 293 T-REx cell pools expressing tetracycline-regulated, BirA*-tagged WT, or catalytically inactive mutant ClpP proteins were generated. Cell pools expressing the BirA* epitope tag alone or BirA* fused to the unrelated mitochondrial enzyme OTC were also created for use as negative controls. 293 T-REx cells (at $60% confluence) were treated with 1 mg/ml tetracycline and 50 mM biotin for 24 hr to induce transgene expression and effect biotinylation of nearby polypeptides. Cells were scraped into PBS, pooled, washed twice in 25 ml PBS, and collected by centrifugation at 1000 3 g for 5 min at 4 C. Cell pellets were lysed in 5 ml ice-cold modified RIPA buffer. 250 U benzonase (EMD Millipore) was added, and biotinylated proteins were isolated. The resulting supernatant was incubated with 30 ml of (RIPA-equilibrated) streptavidinSepharose beads (GE Healthcare) with end-over-end rotation for 2 hr at 4 C.
Beads were washed seven times with 1 ml of 50 mM ammonium bicarbonate (pH 8.0) prior to tryptic digestion.
Mass Spectrometry to Identify ClpP-Interacting Proteins
One microgram of MS-grade L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) trypsin (Promega) dissolved in 70 ml of 50 mM ammonium bicarbonate (pH 8.3) was added to the streptavidin-Sepharose beads and incubated at 37 C overnight. The eluate was collected, and beads were washed twice in 100 ml of 50 mM ammonium bicarbonate. The combined eluate was lyophilized and then resuspended in 0.1% formic acid. Liquid chromatography (LC) analytical columns (75-mm inner diameter) and pre-columns (150-mm inner diameter) were made in-house from fused silica capillary tubing from InnovaQuartz and packed with 100 Å C18-coated silica particles (Magic, Michrom Bioresources). Peptides were subjected to nano liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) using a 95-min reverse-phase (10%-30% acetonitrile, 0.1% formic acid) buffer gradient running at 250 nl/min on a Proxeon EASY-nLC pump in-line with a hybrid linear quadrupole ion trap (Velos LTQ) Orbitrap mass spectrometer (Thermo Fisher Scientific). A parent ion scan was performed in the Orbitrap using a resolving power of 60,000. Simultaneously, the 20 most intense peaks were selected for MS/MS (minimum ion count of 1,000 for activation) using standard collision-induced dissociation (CID) fragmentation. Fragment ions were detected in the LTQ. Dynamic exclusion was activated so that MS/MS of the same mass to charge ratio (m/z) (within a 10-ppm window, exclusion list size 500) detected two times within 15 s were excluded from analysis for 30 s. For protein identification, Thermo.RAW files were converted to the .mzXML format using Proteowizard as part of the trans-proteomic pipeline (Keller and Shteynberg, 2011) . For each search, the iProphet probability at a 1% error rate was used as a cutoff value to generate statistical analysis of interactomes (SAINT)-compatible input files. SAINT parameters were as follows: 5,000 iterations, low mode off, minFold 1, and normalization on Choi et al., 2011) .
Via the ProHits suite (Liu et al., 2010 (Liu et al., , 2012 , MS data were analyzed using the X!Tandem database search algorithm, and the resulting peptide identifications were subjected to iProphet analysis within the transproteomic pipeline (Keller and Shteynberg, 2011) . Using BirA*-only cell data as a control for endogenous biotinylated proteins and polypeptides that interact non-specifically with the solid phase support, the BirA*-ClpP data were subjected to SAINT (Choi et al., 2011) to identify bona fide interacting partners. Polypeptides identified with an iProphet confidence value of >0.8 (reflecting an $1% error rate) and assigned a maximum SAINT confidence value of >0.80 are shown in Figure S3A .
The network of proteins that interacted with WT or catalytically inactive ClpP preferentially over OTC or empty vector were defined using GeneMANIA 3.3.1, Cytoscape 3.1.0 (Montojo et al., 2010) . Preferential interactions compared with OTC or empty vector were identified in 293 T-REx cells using the BirA* tagging method.
Bacterial and Human ClpP Activity Bacterial ClpP was purified from E. coli as described previously (Kimber et al., 2010) . To measure ClpP peptidase activity, 1 mM ClpP (monomer concentration) was dissolved in assay buffer (50 mM Tris-Cl [pH 8.0], 200 mM KCl, and 1 mM DTT) with 0.5 mM succinyl-leucine-tyrosine-7-amino-4-methylcoumarin (Suc-LY-AMC). This mixture was then plated at 50 ml/well in a 96-well plate and read for fluorescence at 2-min intervals for 1 hr at 360/460 nm. The rate of ClpP was determined by calculating the slope (in the linear range).
Human recombinant ClpP (1.2 mM) and ClpX (1.0 mM) were combined and dissolved in assay buffer consisting of 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.5), 5 mM MgCl 2 , 5 mM KCl, 0.03% Tween 20, and 10% glycerol with an ATP regeneration system of 16 mM creatine phosphate and 13 U/ml creatine kinase. 3 mM ATP was added along with the ClpX substrate, casein-fluorescein isothiocyanate (FITC, 4.5 mM). All components were mixed and covered from light at 37 C for 5 min. The mixture was then plated at 200 ml/well in triplicates in a 96-well plate with or without ClpP inhibitors. Fluorescence at 485/535 nm was measured at 37 C every 10 min for 6 hr. The rate of ClpP activity was determined by calculating the slope (in the linear range).
Purification of Human ClpP and ClpX
Plasmids encoding human ClpP and ClpX were transformed into B21 Gold DE3 pLys and B21 Gold DE3 bacteria, respectively. Transformed bacteria were plated on Luria broth (LB)-agar plates containing 100 mg/ml ampicillin and incubated overnight at 37 C. The following day, individual colonies were grown overnight at 37 C in LB medium containing 100 mg/ml ampicillin (ClpP) or 85 mg/ml chloramphenicol and 100 mg/ml ampicillin (ClpX). ClpP and ClpX expression were induced with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) in Terrific medium without antibiotics. Bacteria were collected after 4 hr, and the pellet was frozen at À70 C. ClpP and ClpX proteins were purified on Ni-agarose using lysis buffer (25 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10% Glycerol, 5 mM mercaptoethanol, and 10 mM imidazole), wash buffer (25 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10% Glycerol, 5 mM mercaptoethanol, and 50 mM imidazole), and elution buffer (25 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10% Glycerol, 5 mM mercaptoethanol, and 250 mM imidazole). The proteins were dialyzed for 4 hr at 4 C in dialysis buffer (50 mM Tris-HCl [pH 7.5], 200 mM KCl, 25mM MgCl 2 , 10% g1ycerol, 1 mM DTT, and 0.1 mM EDTA). The recombinant proteins were stored at À70 C.
ClpP Activity in Isolated Mitochondria
Intact mitochondria from cell lines were isolated as described above. The fluorogenic substrate Suc-LY-AMC (0. , and 2 mM ATP). This mixture was plated at 50 ml/well in a 96-well plate, and fluorescence was measured at 2-min intervals for 1 hr (360/460nm). The rate of ClpP activity was determined by calculating the slope (in the linear range).
Assessment of Anti-Leukemia Activity of A2-32-01 in Mouse Models of Human Leukemia OCI-AML2 human leukemia cells (5 3 10 5 ) were injected subcutaneously into the flanks of male SCID mice (Ontario Cancer Institute). When the tumors were palpable, mice were treated with A2-32-01 or vehicle control (corn oil) by i.p. injection (300 mg/kg twice daily for 5 of 7 days) for 10 days (n = 10/group). Tumor volume was measured using caliper measurements at the end of the experiment. Mice were sacrificed, and organs were harvested, fixed with 10% buffered formalin, embedded, sectioned, and stained with H&E. The stained samples were scanned using Aperio Scanscope XT at 103 magnification and analyzed using Aperio ImageScope.
To assess the effect of A2-32-01 on complex II activity in vivo, OCI-AML2 human leukemia cells (5 3 10 5 ) were injected subcutaneously into the flanks of male SCID mice (Ontario Cancer Institute). When the tumors were palpable, mice were treated with A2-32-01 or vehicle control (corn oil) by i.p. injection (300 mg/kg daily) for 5 days (n = 4/group). After 5 days, tumors were excised, and complex II activity was measured as above.
To assess A2-32-01 in mouse models of primary AML engraftment, a frozen aliquot of AML cells was thawed, counted, and re-suspended in PBS, and 2.5 3 10 6 viable trypan blue-negative cells were injected into the right femur of 10 week-old female NOD-SCID mice that had been irradiated 24 hr previously with 208 rad from a 137 Cs source and injected with 200 mg anti-mouse CD122. Two weeks after injection of AML cells, mice were treated with A2-32-01 (300 mg/kg by i.p. injection) or vehicle control (n = 10/group) 3 of 7 days for 4 weeks. Mice were then sacrificed, and the cells were flushed from the femora. Engraftment of human AML cells into the marrow of the non-injected left femur was assessed by enumerating the percentage of human CD45 + CD33 + CD19 À cells by flow cytometry using the BD Biosciences
FACSCalibur. Data were analyzed with FlowJo version 7.7.1 (Tree Star). All animal studies were carried out according to the regulations of the Canadian Council on Animal Care and with the approval of the Ontario Cancer Institute animal ethics review board.
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